Aservo™ EquiHaler™, industry-first therapy for severe equine asthma, now available in Canada
Aservo™ EquiHaler™, industry-first therapy for severe equine asthma, now available in Canada
Search
Livestock
Livestock
Hypertension
Hypertension
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim increases commitments to sustainable development
Parasiticides
Science and Innovation - Animal Health Innovation - Parasiticides
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
Equine
Equine
GPP
GPP
Heart Failure
Heart Failure
Protect your dog from parasites, inside and out
Protect your dog from parasites, inside and out
Patient Centricity
Patient Centricity
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Our Responsibility
Our Responsibility
Bovine
Bovine
Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients
Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients
Pets
Pets
Diabetes
Diabetes
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Vaccine protection against different PRRS virus strains
Vaccine protection against different PRRS virus strains
New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Twenty years of controlling Lawsonia intracellularis
Twenty years of controlling Lawsonia intracellularis